Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]염증성 장 질환 환자에서 정맥 주사에서 피하 베돌리주맙으로 전환 [TRAVELESS]Article Published on 2022-07-142022-09-12 Journal: Journal of Crohn's & colitis [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adverse drug reactions appear baseline benefit biochemical bowel calprotectin clinically Cohort cohort of patients declining Disease activity dose effective evaluate expected Health Service IBD increase in Inflammatory bowel disease injection intravenous measure offered outcome Patient Patient satisfaction reaction reason reduction reported risk factor routine clinical care Safe SARS-COV-2 infection statistically significant statistically significant difference Subcutaneous switching TRAVELESS Treatment unlikely vedolizumab Week [DOI] 10.1093/ecco-jcc/jjab224 PMC 바로가기 [Article Type] Article
Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease종양 괴사 인자-α 길항제의 사용은 염증성 장 질환이 있는 백신 접종 환자에서 SARS-CoV-2에 대한 약화된 IgG 항체 반응과 관련이 있습니다Observational Study Published on 2022-07-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Against age antagonist antagonists anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody concentrations Antibody titer Antibody titers Biologicals Blood blood sampling bowel Characteristics clinical Clinical characteristics Combination completion Concentration COVID-19 Crohn's disease defined demonstrated detectable disease Effect elapsed geometric geometric mean IBD IgG IgG antibodies IgG antibody IgG antibody titer IgG antibody titers immune response immunoassay immunomodulating Immunosuppressive medication immunosuppressive medications increased risk independent independent of Inflammatory Inflammatory bowel disease medication Microparticle monotherapy Most patients mRNA mRNA vaccines mRNA-based vaccine mRNA-based vaccines Multivariable models Patient patient age patients patients treated prospective observational cohort quantitative determination RBD receive receiving Receptor-binding domain regimen response S1 subunit sampling SARS-CoV-2 SARS-COV-2 infection Seroconversion serological response significantly lower Spike protein the receptor-binding domain the S1 subunit the spike protein titer TNF-α-antagonists treated Treatment Tumor ulcerative colitis vaccination Vaccine vector was used were measured were recorded [DOI] 10.3389/fimmu.2022.920333 PMC 바로가기 [Article Type] Observational Study
Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease염증성 장 질환이 있는 소아 및 젊은 성인의 감염 또는 예방 접종 후 SARS-CoV-2에 대한 항체 반응Article Published on 2022-07-012022-09-11 Journal: Inflammatory bowel diseases [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] ACE2 age angiotensin Antibody Response approved binding domain biologic biologic therapies Cell characterization children clinical symptom Cohort Crohn's disease disease dynamic range embryonic kidney enrolled enzyme expressing flow cytometry fluorescent HEK-293 Hospitalized IBD IgG antibodies IgG antibody IgG positivity IgG response immunization immunoassay Inflammatory bowel disease infliximab lentivirus less longitudinal cohort study measure Most patients natural infection neutralization antibodies Neutralization antibody Neutralization assay Neutralizing antibodies neutralizing antibody Patient PCR Pediatric patient performed post infection Protective Protein binding RBD IgG receiving Receptor binding domain Reinfection response risk robust S-RBD SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 spike protein receptor binding domain serum significantly lower Spike protein subject the spike protein therapy ulcerative colitis vaccination Vaccines variant vedolizumab was used wild type [DOI] 10.1093/ibd/izab207 PMC 바로가기 [Article Type] Article
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease염증성 장 질환 환자에서 SARS-CoV-2 mRNA 백신 접종 후 6개월 후 항체 반응Article Published on 2022-07-012022-09-11 Journal: Clinical gastroenterology and hepatology : the off [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-spike antibody anti-spike antibody response antibody kinetics Antibody Response completion coronavirus detectable examined IBD Immunosuppression immunosuppressive medications Inflammatory bowel disease Kinetics medication moderate moderate to severe Month mRNA Patient receive response SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine severe acute respiratory syndrome Coronavirus shown subset the SARS-CoV-2 therapy vaccination Vaccinations vaccine response [DOI] 10.1016/j.cgh.2021.12.045 PMC 바로가기 [Article Type] Article
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic임상 실습의 최근 발전: COVID-19 대유행 중 염증성 장 질환 관리Review Published on 2022-07-012022-09-11 Journal: Gut [Category] COVID19(2023년), SARS, 치료기술, [키워드] acquisition adverse outcome adverse outcomes antibody booster dose bowel Breakthrough infection breakthrough infections Cancer cancers Corticosteroid Corticosteroids COVID-19 COVID-19 in patient COVID-19 pandemic Crohn's disease de novo decrease develop diagnoses disease course dose Evidence Future General population Guidance hospitalisation hospitalisations Humoral response humoral responses IBD immune immune response immunosuppressive therapies immunosuppressive therapy increased risk Inflammatory Inflammatory bowel disease management medication medications Necrosis outcome outcomes pandemic Patient patients potential risk primary dose raised receive recent remained Research risk risk of COVID-19 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines TNF treated Treatment ulcerative ulcerative colitis Vaccine vaccine response Vaccines [DOI] 10.1136/gutjnl-2021-326784 PMC 바로가기 [Article Type] Review
The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy염증성 장 질환에서 SARS-CoV-2 백신 접종에 대한 T-세포 반응은 항-TNF 요법으로 증가Article Published on 2022-07-012022-09-12 Journal: Inflammatory bowel diseases [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract antibody Antibody Response biologic bowel IBD IBD biologic therapy Inflammatory Inflammatory bowel disease response SARS-CoV-2 T-cell T-cell Response TCR TCR clonal vaccination [DOI] 10.1093/ibd/izac071 PMC 바로가기 [Article Type] Article
Risks of SARS-CoV-2 Infection and Immune Response to COVID-19 Vaccines in Patients With Inflammatory Bowel Disease: Current Evidence염증성 장 질환 환자의 코로나19 백신에 대한 SARS-CoV-2 감염 및 면역 반응의 위험: 현재 증거Review Published on 2022-06-232022-09-11 Journal: Frontiers in Immunology [Category] 변종, [키워드] aberrant immune response Affect available data bowel Combination condition Corticosteroid Corticosteroids Course COVID-19 COVID-19 vaccine COVID-19 vaccines Crohn's disease Crohn’s disease current disease dysregulated environmental factors Factor forms healthy subjects IBD immune immune response immunogenicity Immunosuppressant immunosuppressants increased risk infection with SARS-CoV-2 infections Inflammatory Inflammatory bowel disease inflammatory bowel diseases intestinal intestinal disease less majority many case many cases measure modify Necrosis occur pandemic Pathogens Patient patients treated PROTECT Psychological psychological factors question receive reduce reduced response risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants significantly increased subject susceptibility susceptibility to infection susceptible individual therapy ulcerative colitis Vaccine [DOI] 10.3389/fimmu.2022.933774 PMC 바로가기 [Article Type] Review
Boosting corrects a memory B cell defect in SARS-CoV-2 mRNA-vaccinated patients with inflammatory bowel disease부스팅은 염증성 장 질환이 있는 SARS-CoV-2 mRNA 백신 접종 환자의 기억 B 세포 결함을 수정합니다Article Published on 2022-06-222022-09-12 Journal: JCI Insight [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Adaptive immunity antibody antibody affinity B cell B lymphocyte bowel Cell cellular Control control group controls COVID-19 elevated generate healthy controls IBD identify immunology Inflammatory bowel disease maturation memory memory B memory B cell mRNA vaccination neutralizing antibody Patient produced Receptor binding SARS-CoV-2 SARS-CoV-2 spike serum antibody vaccination [DOI] 10.1172/jci.insight.159618 PMC 바로가기 [Article Type] Article
Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies면역 조절 요법을 받는 환자에서 유리한 백신 유도 SARS-CoV-2 특이적 T 세포 반응 프로파일Article Published on 2022-06-152022-09-12 Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] B.1.1.529 biologic bowel catalyst Cellular immune response characterized COVID-19 COVID-19 vaccination cytokine demonstrated disease healthy individuals humoral IBD immune immunology Immunotherapy Infectious disease Inflammatory bowel disease inhibitor inhibitors lack magnitude methotrexate mRNA Mutation omicron Patient preserved reduced response SARS-CoV-2 spike-specific T cell sustained T cell T cell response therapy TNF treated treated patient Treatment vaccination [DOI] 10.1172/JCI159500 PMC 바로가기 [Article Type] Article
IBD therapeutics: what is in the pipeline?Review Published on 2022-06-152024-09-04 Journal: Journal of Investigative Dermatology [Category] 대상포진, [키워드] Crohn's disease IBD ulcerative colitis [DOI] 10.1136/flgastro-2022-102130 PMC 바로가기 [Article Type] Review